ETS2 Antibody

What is ETS2 and why is it a significant research target?

ETS2 (v-ets erythroblastosis virus E26 oncogene homolog 2) is a transcription factor within the ETS family that functions as a central regulator of gene expression. It contains a conserved ETS DNA-binding domain that recognizes the GGAA/T core motif (Ets-binding site or EBS) in gene promoters . ETS2 plays crucial roles in multiple cellular processes including proliferation, differentiation, apoptosis, and angiogenesis .

Recent research has identified ETS2 as a central regulator of human inflammatory macrophages, with significant implications for inflammatory diseases . Additionally, ETS2 has been implicated in tumor suppression in lung cancer, highlighting its contextual role in cancer biology . These diverse functions make ETS2 a high-value target for research across multiple fields including immunology, oncology, and developmental biology.

What are the key characteristics of commercial ETS2 antibodies currently available?

Several validated ETS2 antibodies are available for researchers, each with specific characteristics:

Most ETS2 antibodies detect a protein of approximately 53 kDa, consistent with the calculated molecular weight of the full-length protein (469 amino acids) . The observed molecular weight in experimental contexts typically confirms this prediction .

What are the recommended starting dilutions for different experimental applications?

Based on validated protocols, the following dilutions represent good starting points for various applications:

It is strongly recommended to optimize these dilutions for each specific experimental context and sample type to achieve optimal signal-to-noise ratios .

What are the optimal sample preparation methods for detecting ETS2 in different cell and tissue types?

Sample preparation methods should be tailored to the experimental application and tissue/cell type:

For protein extraction and Western blotting:

• Cell monolayers should be washed twice with PBS, harvested and lysed with ice-cold RIPA buffer

• Protein lysates (20 μg recommended) should be subjected to SDS-PAGE

• Most published research utilizes β-ACTIN as a loading control for ETS2 detection

• Band intensities can be quantified relative to β-ACTIN using Image J software

For immunohistochemistry:

• For formalin-fixed paraffin-embedded (FFPE) tissues, antigen retrieval is critical

• Preferred methods include either TE buffer (pH 9.0) or citrate buffer (pH 6.0)

• Following antigen retrieval, standard IHC protocols with optimized primary antibody dilutions (1:50-1:500) should be followed

• For scoring, a 4-value intensity system (0=none, 1=weak, 2=moderate, 3=strong) combined with percentage (0%-100%) extent of reactivity has been validated

For immunofluorescence:

• Paraformaldehyde fixation has been validated for cell lines such as HeLa

• Co-staining with cytoskeletal markers (such as alpha-tubulin) can provide useful reference for cellular localization

How can I validate ETS2 antibody specificity for my research application?

Proper validation of antibody specificity is essential and can be accomplished through multiple complementary approaches:

• Positive and negative controls:

  • Use cell lines with known ETS2 expression (K-562, HeLa, MCF-7, PC-3 for positive controls)

  • Include samples processed identically but omitting the primary antibody as negative controls

  • Consider using FFPE pellets from cell lines with confirmed ETS2 expression

• Genetic validation:

  • CRISPR-Cas9 mediated ETS2 knockout or knockdown can provide definitive validation

  • Validated approaches include using two distinct gRNAs targeting different ETS2 exons to control for off-target effects

  • Efficiency of knockdown can be confirmed by qPCR and/or Western blot

• Competing peptide blocking:

  • Pre-incubation of the antibody with its immunizing peptide should abolish specific staining

  • This approach can be used for both immunohistochemistry and Western blotting

• Cross-validation with multiple antibodies:

  • Use antibodies from different vendors or those targeting different epitopes

  • Concordant results with multiple antibodies increases confidence in specificity

What is the best approach for studying ETS2 phosphorylation and its functional significance?

ETS2 is regulated by post-translational modifications, with phosphorylation being particularly important for its transcriptional activity:

• Detection of phosphorylated ETS2:

  • Specific phospho-ETS2 antibodies targeting the Threonine-72 (Thr-72) residue are available

  • This site is regulated by MAP kinase phosphorylation and is crucial for ETS2 activity

  • Western blotting with phospho-specific antibodies coupled with total ETS2 detection provides information on activation state

• Functional studies:

  • The Ets2 A72 mutation (converting Thr-72 to Alanine) prevents phosphorylation

  • Gene targeting approaches have been used to introduce this mutation, enabling functional studies

  • The effects of phosphorylation status on downstream target gene expression can be assessed through ChIP-seq or RNA-seq experiments

• Relationship to signaling pathways:

  • Analyze parallel activation of ERK1/2 and other MAP kinases

  • Pharmacological inhibitors of the MAPK pathway can be used to modulate ETS2 phosphorylation

  • Correlation between MET activation and ETS2 phosphorylation has been observed, suggesting interconnected signaling

How can ChIP assays be optimized for studying ETS2 genomic binding sites?

Chromatin Immunoprecipitation (ChIP) is a powerful technique for identifying ETS2 binding sites across the genome:

• Protocol optimization:

  • Cross-linked ChIP has been successfully performed with various cell lines, including MCF-7

  • Typically use 5 μg of anti-ETS2 antibody per experiment, with rabbit IgG as a control

  • When traditional ChIP-seq proves challenging, CUT&RUN (Cleavage Under Targets and Release Using Nuclease) offers an alternative approach that doesn't require fixation steps that can potentially alter protein epitopes

• Target validation:

  • Primers targeting known ETS2 binding sites, such as those in the PTHrP promoter, can serve as positive controls

  • The canonical ETS2 binding motif (GGAA/T core) should be present in validated target regions

  • ETS2 binding regions typically show 90% localization to active regulatory regions (promoters or enhancers)

• Data analysis:

  • ETS2 ChIP-seq peaks show significant enrichment for the canonical ETS2 motif (4.02-fold versus global controls)

  • Co-enrichment for motifs of known ETS2 interactors (FOS, JUN, NF-κB) is often observed

  • ETS2 binding has been detected at genes involved in multiple inflammatory functions, including NCF4 (ROS production), NLRP3 (inflammasome activation), and TLR4 (bacterial pattern recognition)

What approaches are most effective for studying ETS2's role in macrophage inflammation?

Recent research has established ETS2 as a central regulator of inflammatory responses in macrophages:

• Loss-of-function studies:

  • CRISPR-Cas9 based approaches with two different gRNAs targeting different ETS2 exons (achieving ~90% and ~79% editing efficiency)

  • This approach effectively reduced ETS2 expression without affecting cell viability or macrophage marker expression

  • Key readouts include pro-inflammatory cytokine production (IL-6, IL-8, IL-1β), phagocytosis (using fluorescently labeled particles), and extracellular reactive oxygen species (ROS) production

• Gain-of-function studies:

  • Controlled overexpression through transfection of in vitro transcribed mRNA (modified to minimize immunogenicity)

  • Use of reverse complement as control (controlling for mRNA quantity, length, and purine/pyrimidine composition)

  • Combined with low-dose lipopolysaccharide to initiate a low-grade inflammatory response that can be amplified

• Comprehensive assessment of inflammatory pathways:

  • RNA-seq to characterize transcriptional responses

  • All inflammatory pathways (macrophage activation, cytokine production, ROS production, phagocytosis, migration) show dose-dependent induction by ETS2 overexpression

  • ETS2 targets include HIF1A, PFKFB3, and other glycolytic genes, indicating that ETS2 induces metabolic changes as part of a complex inflammatory program

How can I best investigate ETS2's role in cancer pathogenesis?

ETS2 has context-dependent roles in cancer that require careful experimental design:

• Expression analysis in clinical samples:

  • IHC analysis of lung adenocarcinomas and normal adjacent tissue has revealed differences in ETS2 expression

  • Quantification using a 4-value intensity score (0=none, 1=weak, 2=moderate, 3=strong) and percentage extent of reactivity provides reliable assessment

  • Kaplan-Meier survival analysis can correlate ETS2 expression with patient outcomes

• Multivariate analysis:

  • Association of ETS2 IHC protein expression with patient outcome (time to recurrence) can be estimated using the Kaplan-Meier method

  • Comparisons among groups should use log-rank statistical tests

  • Multivariate Cox proportional hazard models can assess the effects of ETS2 expression on time to recurrence, adjusted for tumor stage

• Relationship with oncogenic pathways:

  • Correlation between ETS2 expression and oncogene activation (e.g., MET phosphorylation) provides insights into functional interactions

  • Simultaneous detection of ETS2 and phospho-MET (Y1234/Y1235) has revealed significant associations in lung cancer

  • Western blot analysis of downstream signaling molecules (ERK1/2, phosphorylated-ERK1/2) helps place ETS2 within signaling networks

What are common issues encountered with ETS2 immunohistochemistry and how can they be resolved?

Researchers frequently encounter specific challenges when performing ETS2 immunohistochemistry:

• Background staining issues:

  • High background can result from insufficient blocking or antibody concentrations that are too high

  • Solution: Optimize blocking conditions (typically 5-10% normal serum matching the host species of the secondary antibody) and titrate primary antibody

  • Use validated dilution ranges (1:50-1:500) as starting points

• Weak or absent staining:

  • Often results from inadequate antigen retrieval or tissue fixation issues

  • Solution: Test both recommended antigen retrieval methods (TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Extend retrieval time if necessary (typically 15-20 minutes)

  • Consider testing multiple antibodies targeting different epitopes

• Specificity concerns:

  • Nonspecific binding can complicate interpretation

  • Solution: Include appropriate positive controls (cell lines with known ETS2 expression) and negative controls (omission of primary antibody)

  • Consider using FFPE pellets from lung cancer cell lines displaying positive ETS2 expression as positive controls

• Quantification challenges:

  • Subjectivity in scoring can introduce variability

  • Solution: Use validated scoring systems (4-value intensity score combined with percentage reactivity)

  • Consider automated image analysis when possible

  • Have multiple trained observers score independently to ensure reproducibility

How should I interpret discrepancies in ETS2 expression data between different experimental techniques?

When faced with conflicting results across experimental methods, consider these methodological factors:

• Western blot vs. IHC discrepancies:

  • Western blot detects denatured protein from whole tissue/cell lysates, while IHC preserves spatial context

  • Solution: Ensure sample preparation consistency and validate antibody performance in each technique separately

  • Consider that post-translational modifications may affect epitope recognition differently in each method

  • Western blot typically provides quantitative data on the 53 kDa ETS2 protein

• mRNA vs. protein expression differences:

  • Discrepancies often reflect post-transcriptional regulation

  • Solution: Combine qPCR with protein detection methods

  • Time-course experiments may reveal temporal relationships between transcription and translation

  • For CRISPR experiments, on-target editing of approximately 90% and 79% with two different gRNAs has been achieved, effectively reducing ETS2 expression

• Cell line vs. tissue sample variations:

  • Cell lines may not fully recapitulate in vivo expression patterns

  • Solution: Validate findings across multiple cell lines and primary samples

  • Confirm antibody reactivity in both contexts (antibodies like 12280-1-AP have been validated in both cell lines and tissue samples)

  • Use species-appropriate positive controls (validated in human, mouse, and rat samples)

How can I study ETS2's role in autoregulation and enhancer activity?

Recent findings suggest ETS2 participates in regulating its own expression:

• Enhancer binding studies:

  • ETS2 binding has been detected at the chr21q22 enhancer, suggesting potential autoregulation

  • CUT&RUN methodology has proven effective for identifying these binding patterns

  • ChIP-seq analysis reveals that ETS2 peaks are mostly located in active regulatory regions (90% in promoters or enhancers)

• Functional validation:

  • Manipulating ETS2 expression alters enhancer activity in a manner consistent with positive autoregulation

  • Reporter assays with enhancer constructs can directly assess ETS2's impact on its own regulatory elements

  • CRISPR-based enhancer editing can demonstrate functional relevance in endogenous contexts

• Interaction with other factors:

  • ETS2 can interact synergistically with other transcription factors like PU.1

  • Co-immunoprecipitation studies can identify relevant protein-protein interactions

  • Sequential ChIP (Re-ChIP) can assess co-occupancy at specific genomic loci

What are the most promising approaches for investigating ETS2's role in metabolic reprogramming during inflammation?

ETS2 regulates multiple metabolic genes essential for inflammatory responses:

• Metabolic profiling:

  • Measure glycolytic parameters in cells with manipulated ETS2 levels

  • ETS2 targets include HIF1A, PFKFB3, and other glycolytic genes (GPI, HK2, HK3)

  • Seahorse analysis can quantify glycolytic flux and oxidative phosphorylation

• Integrated multi-omics:

  • Combine RNA-seq, ChIP-seq, and metabolomics data

  • This integrated approach has revealed that ETS2 directly binds to and regulates metabolic genes

  • 48.3% (754/1,560) of genes dysregulated after ETS2 disruption and 50.3% (1,078/2,153) of genes dysregulated after ETS2 overexpression contain an ETS2-binding peak

• Targeted intervention:

  • Use inhibitors of specific metabolic pathways to determine functional requirements

  • Genetic manipulation of downstream targets can establish causality

  • The metabolic changes appear to be directly induced as part of a complex inflammatory program coordinated by ETS2

What are cutting-edge techniques for studying ETS2 in single cells and spatial contexts?

Newer methodological approaches offer unprecedented insights into ETS2 biology:

• Single-cell techniques:

  • Single-cell RNA-seq can reveal cell-specific expression patterns

  • CyTOF or spectral flow cytometry with intracellular ETS2 staining can identify rare cell populations

  • Consider that ETS2 has been identified as a central regulator of human inflammatory macrophages, suggesting important cell-type specific functions

• Spatial transcriptomics and proteomics:

  • Techniques like Visium or GeoMx can map ETS2 expression within tissue architecture

  • Multiplexed immunofluorescence can simultaneously detect ETS2 and interacting partners or downstream targets

  • These approaches are particularly valuable for heterogeneous tissues where ETS2 function may vary by microenvironment

• Live-cell imaging:

  • ETS2 fusion with fluorescent proteins enables real-time tracking

  • Optogenetic control of ETS2 activity allows precise temporal manipulation

  • These approaches can reveal dynamic aspects of ETS2 function, particularly relevant for inflammatory responses which involve complex temporal regulation